70% was achieved using 10% of PVA without compromising protein stability. We tried to increase the protein loading to 5%, but surprisingly the encapsulation failed when the protein nanoparticles suspended in PLGA solution were added to the PVA solution. However, using PLGA with a co-polymer ratio of 50:50 resulted in nanoencapsulation, but the encapsulation efficiency needed improvement. PARP inhibitor drugs When we increased the volume of the diffusing phase to accomplish faster particle hardening,

the encapsulation efficiency increased substantially to >80% at a 1:40 volume ratio of dispersing-to-diffusing phase (Table 4). We also tested the polymer concentration in this context. It has been shown that a higher polymer concentration leads to higher encapsulation efficiency and larger size of the nanoparticles [31,32]. At a high PLGA concentration, the viscosity of the diffusing phase increases which

should result in improved encapsulation by reduction of lysozyme nanoparticles leaking into the dispersing phase. Indeed, we found increasing lysozyme encapsulation efficiency at increasing polymer concentration as expected (Table 5). In a similar fashion encapsulation efficiency was improved for a-chymotrypsin. Changing the polymer concentration proved only somewhat successful in this case, possibly because at increased PLGA concentrations the polymer shell thickness also increased [33]. The encapsulation efficiency remained with a maximum of 30% too low for practical purposes (Table 5). Reducing the particle size Selleckchem A 1210477 of a-chymotrypsin by employing a lower protein concentration of 15 mg/ml (Table 2) resulted in an improved encapsulation efficiency of 74% (Table 6). The data show how sensitive the results respond to encapsulation conditions in this method highlighting the fact that encapsulation likely has to be optimized in a similar fashion Cobimetinib cost as described here for other proteins. However, there are only a few processing parameters requiring adjustment

and the process is straight forward and reproducible as demonstrated by the small standard deviations obtained for encapsulation parameters under optimized conditions. The optimum conditions to encapsulate lysozyme and a-chymotrypsin in PLGA nanoparticles are summarized in Table 7. The size of the protein loaded PLGA particles obtained by dynamic light scattering was ca. 300–400▒nm in diameter (Table 7). However, while lysozyme encapsulation afforded a highly active enzyme, substantial enzyme inactivation and formation of buffer-insoluble aggregates were observed for a-chymotrypsin. The formation of buffer-insoluble aggregates and loss in specific activity found for a-chymotrypsin is similar to results obtained before upon a-chymotrypsin encapsulation in PLGA microspheres using a s/o/w technique [27,28,[34], [35] and [36]]. The use of stabilizing additives (e.g.